Edition:
United Kingdom

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.40USD
17 Jul 2018
Change (% chg)

-- (--)
Prev Close
$1.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
122,003
52-wk High
$2.65
52-wk Low
$0.69

Chart for

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II... (more)

Overall

Beta: -0.74
Market Cap(Mil.): $32.25
Shares Outstanding(Mil.): 23.04
Dividend: --
Yield (%): --

Financials

  VTGN.OQ Industry Sector
P/E (TTM): -- 29.21 33.15
EPS (TTM): -1.25 -- --
ROI: -235.87 13.66 13.23
ROE: -414.00 15.51 15.27

BRIEF-VistaGen Therapeutics Reports Qtrly Loss Per Share $‍0.25​

* VISTAGEN THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS

12 Feb 2018

BRIEF-Vistagen Therapeutics ‍Prepares To Initiate Its Phase 2 Study Of Av-101 For Major Depressive Disorder​

* VISTAGEN THERAPEUTICS INC - ‍PREPARES TO INITIATE ITS PHASE 2 STUDY OF AV-101 FOR MAJOR DEPRESSIVE DISORDER​ Source text for Eikon: Further company coverage:

29 Jan 2018

Competitors

Earnings vs. Estimates